JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE) ›› 2021, Vol. 41 ›› Issue (9): 1215-1221.doi: 10.3969/j.issn.1674-8115.2021.09.012
• Clinical research • Previous Articles
Jing-jing ZHANG1(), Chao-yu ZHU2, Yuan-yuan XIAO2, Fu-song JIANG2, Qing-ge GAO2, Yun-yun FANG2, Li WEI2(
)
Received:
2021-04-13
Online:
2021-08-24
Published:
2021-08-24
Contact:
Li WEI
E-mail:18616829306@163.com;18930173636@189.cn
Supported by:
CLC Number:
Jing-jing ZHANG, Chao-yu ZHU, Yuan-yuan XIAO, Fu-song JIANG, Qing-ge GAO, Yun-yun FANG, Li WEI. Association study of variation of glucagon-like peptide-1 receptor gene rs3765467 and type 2 diabetes mellitus[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(9): 1215-1221.
Add to citation manager EndNote|Ris|BibTeX
URL: https://xuebao.shsmu.edu.cn/EN/10.3969/j.issn.1674-8115.2021.09.012
Item | T2DM group (n=318) | Control group (n=145) | χ2/t value | P value |
---|---|---|---|---|
Gender (M/F)/n | 158/160 | 58/87 | 3.754 | 0.053 |
Age/year | 54.53±10.79 | 53.12±6.56 | 1.725 | 0.085 |
BMI/(kg·m-2) | 25.84±3.72 | 23.73±3.26 | 5.755 | 0.000 |
SBP/mmHg | 135.81±19.41 | 122.62±13.99 | 8.036 | 0.000 |
DBP/mmHg | 79.03±12.71 | 78.11±8.86 | 0.876 | 0.381 |
FBG/(mmol·L-1) | 8.76±2.39 | 5.28±0.35 | 17.186 | 0.000 |
2h PG/(mmol·L-1) | 12.81±4.78 | 6.39±1.14 | 21.640 | 0.000 |
HbA1c/% | 9.51±2.54 | 5.60±0.29 | 25.061 | 0.000 |
GA/% | 24.96±12.70 | 13.22±1.14 | 14.456 | 0.000 |
HDL-Ch/(mmol·L-1) | 1.06±0.28 | 1.27±0.34 | -6.767 | 0.000 |
LDL-Ch/(mmol·L-1) | 3.26±0.83 | 3.07±0.71 | 2.385 | 0.018 |
TC/(mmol·L-1) | 5.17±1.40 | 4.87±0.85 | 2.744 | 0.006 |
TAG/(mmol·L-1) | 1.82(1.27, 3.03) | 1.15 (0.74, 1.77) | 7.425 | 0.000 |
FINS/(mU·L-1) | 10.20 (6.20, 15.56) | 6.55 (4.25, 8.72) | 6.919 | 0.000 |
2 h INS/(mU·L-1) | 38.46 (20.04, 65.86) | 30.66 (18.84, 51.65) | 1.824 | 0.068 |
HOMA-IR | 3.81 (2.33, 6.26) | 1.52 (0.99, 2.07) | 11.257 | 0.000 |
HOMA-β | 44.10 (24.96, 76.02) | 73.96 (48.61, 101.13) | -6.389 | 0.000 |
Tab 1 Clinical characteristics of the study population
Item | T2DM group (n=318) | Control group (n=145) | χ2/t value | P value |
---|---|---|---|---|
Gender (M/F)/n | 158/160 | 58/87 | 3.754 | 0.053 |
Age/year | 54.53±10.79 | 53.12±6.56 | 1.725 | 0.085 |
BMI/(kg·m-2) | 25.84±3.72 | 23.73±3.26 | 5.755 | 0.000 |
SBP/mmHg | 135.81±19.41 | 122.62±13.99 | 8.036 | 0.000 |
DBP/mmHg | 79.03±12.71 | 78.11±8.86 | 0.876 | 0.381 |
FBG/(mmol·L-1) | 8.76±2.39 | 5.28±0.35 | 17.186 | 0.000 |
2h PG/(mmol·L-1) | 12.81±4.78 | 6.39±1.14 | 21.640 | 0.000 |
HbA1c/% | 9.51±2.54 | 5.60±0.29 | 25.061 | 0.000 |
GA/% | 24.96±12.70 | 13.22±1.14 | 14.456 | 0.000 |
HDL-Ch/(mmol·L-1) | 1.06±0.28 | 1.27±0.34 | -6.767 | 0.000 |
LDL-Ch/(mmol·L-1) | 3.26±0.83 | 3.07±0.71 | 2.385 | 0.018 |
TC/(mmol·L-1) | 5.17±1.40 | 4.87±0.85 | 2.744 | 0.006 |
TAG/(mmol·L-1) | 1.82(1.27, 3.03) | 1.15 (0.74, 1.77) | 7.425 | 0.000 |
FINS/(mU·L-1) | 10.20 (6.20, 15.56) | 6.55 (4.25, 8.72) | 6.919 | 0.000 |
2 h INS/(mU·L-1) | 38.46 (20.04, 65.86) | 30.66 (18.84, 51.65) | 1.824 | 0.068 |
HOMA-IR | 3.81 (2.33, 6.26) | 1.52 (0.99, 2.07) | 11.257 | 0.000 |
HOMA-β | 44.10 (24.96, 76.02) | 73.96 (48.61, 101.13) | -6.389 | 0.000 |
Model | T2DM group (n=318) | Control group (n=145) | OR (95 % CI) | P value | Adjusted OR (95 % CI) ① | Adjusted P value① |
---|---|---|---|---|---|---|
Allele | ||||||
G(ref)/n(%) | 496 (78) | 201 (69) | 1 | ‒ | 1 | ‒ |
A/n(%) | 140 (22) | 89 (31) | 0.637 (0.467‒0.871) | 0.005 | 0.587 (0.395‒0.872) | 0.008 |
Genotype | ||||||
GG(ref)/n(%) | 201 (63) | 70 (48) | 1 | ‒ | 1 | ‒ |
GA/n(%) | 94 (30) | 61 (42) | 0.537 (0.352‒0.818) | 0.004 | 0.507 (0.298‒0.864) | 0.012 |
AA/n(%) | 23 (7) | 14 (10) | 0.572 (0.279‒1.173) | 0.127 | 0.484 (0.197‒1.190) | 0.114 |
Dominant model | ||||||
GG(ref)/n(%) | 201 (63) | 70 (48) | 1 | ‒ | 1 | ‒ |
GA+AA/n(%) | 117 (37) | 75 (52) | 0.543 (0.365‒0.808) | 0.003 | 0.502 (0.305‒0.829) | 0.007 |
Recessive model | ||||||
GG+GA(ref)/n(%) | 295 (93) | 131 (90) | 1 | ‒ | 1 | ‒ |
AA/n(%) | 23 (7) | 14 (10) | 0.730 (0.364‒1.463) | 0.374 | 0.630 (0.264‒1.506) | 0.298 |
Tab 2 Association between GLP-1R rs3765467 polymorphism and T2DM susceptibility
Model | T2DM group (n=318) | Control group (n=145) | OR (95 % CI) | P value | Adjusted OR (95 % CI) ① | Adjusted P value① |
---|---|---|---|---|---|---|
Allele | ||||||
G(ref)/n(%) | 496 (78) | 201 (69) | 1 | ‒ | 1 | ‒ |
A/n(%) | 140 (22) | 89 (31) | 0.637 (0.467‒0.871) | 0.005 | 0.587 (0.395‒0.872) | 0.008 |
Genotype | ||||||
GG(ref)/n(%) | 201 (63) | 70 (48) | 1 | ‒ | 1 | ‒ |
GA/n(%) | 94 (30) | 61 (42) | 0.537 (0.352‒0.818) | 0.004 | 0.507 (0.298‒0.864) | 0.012 |
AA/n(%) | 23 (7) | 14 (10) | 0.572 (0.279‒1.173) | 0.127 | 0.484 (0.197‒1.190) | 0.114 |
Dominant model | ||||||
GG(ref)/n(%) | 201 (63) | 70 (48) | 1 | ‒ | 1 | ‒ |
GA+AA/n(%) | 117 (37) | 75 (52) | 0.543 (0.365‒0.808) | 0.003 | 0.502 (0.305‒0.829) | 0.007 |
Recessive model | ||||||
GG+GA(ref)/n(%) | 295 (93) | 131 (90) | 1 | ‒ | 1 | ‒ |
AA/n(%) | 23 (7) | 14 (10) | 0.730 (0.364‒1.463) | 0.374 | 0.630 (0.264‒1.506) | 0.298 |
Model | Male | Female | ||||||
---|---|---|---|---|---|---|---|---|
T2DM group (n=158) | Control group (n=58) | Adjusted OR (95% CI)① | Adjusted P value① | T2DM group (n=160) | Control group (n=87) | Adjusted OR (95% CI) ① | Adjusted P value① | |
Allele | ||||||||
G(ref)/n(%) | 254 (80) | 77 (66) | 1 | ‒ | 242 (76) | 124 (71) | 1 | ‒ |
A/n(%) | 62 (20) | 39 (34) | 0.460 (0.249‒0.852) | 0.013 | 78 (24) | 50 (29) | 0.804 (0.467‒1.387) | 0.433 |
Genotype | ||||||||
GG(ref)/n(%) | 105 (67) | 27 (47) | 1 | ‒ | 96 (60) | 45 (52) | 1 | ‒ |
GA/n(%) | 44 (28) | 25 (43) | 0.439 (0.195‒0.990) | 0.047 | 50 (31) | 34 (39) | 0.677 (0.322‒1.422) | 0.303 |
AA/n(%) | 9 (6) | 6 (10) | 0.258 (0.059‒1.124) | 0.071 | 14 (9) | 8 (9) | 0.837 (0.252‒2.783) | 0.772 |
Dominant model | ||||||||
GG(ref)/n(%) | 105 (67) | 25 (43) | 1 | ‒ | 96 (60) | 45 (52) | 1 | ‒ |
GA+AA/n(%) | 53 (33) | 33 (57) | 0.403 (0.186‒0.871) | 0.021 | 64 (40) | 42 (48) | 0.708 (0.354‒1.417) | 0.330 |
Recessive model | ||||||||
GG+GA(ref)/n(%) | 149 (94) | 52 (90) | 1 | ‒ | 146 (91) | 79 (91) | 1 | ‒ |
AA/n(%) | 9 (6) | 6 (10) | 0.360 (0.086‒1.502) | 0.161 | 14 (9) | 8 (9) | 0.981 (0.307‒3.316) | 0.974 |
Tab 3 Association between GLP-1R rs3765467 polymorphism and T2DM susceptibility in male and female
Model | Male | Female | ||||||
---|---|---|---|---|---|---|---|---|
T2DM group (n=158) | Control group (n=58) | Adjusted OR (95% CI)① | Adjusted P value① | T2DM group (n=160) | Control group (n=87) | Adjusted OR (95% CI) ① | Adjusted P value① | |
Allele | ||||||||
G(ref)/n(%) | 254 (80) | 77 (66) | 1 | ‒ | 242 (76) | 124 (71) | 1 | ‒ |
A/n(%) | 62 (20) | 39 (34) | 0.460 (0.249‒0.852) | 0.013 | 78 (24) | 50 (29) | 0.804 (0.467‒1.387) | 0.433 |
Genotype | ||||||||
GG(ref)/n(%) | 105 (67) | 27 (47) | 1 | ‒ | 96 (60) | 45 (52) | 1 | ‒ |
GA/n(%) | 44 (28) | 25 (43) | 0.439 (0.195‒0.990) | 0.047 | 50 (31) | 34 (39) | 0.677 (0.322‒1.422) | 0.303 |
AA/n(%) | 9 (6) | 6 (10) | 0.258 (0.059‒1.124) | 0.071 | 14 (9) | 8 (9) | 0.837 (0.252‒2.783) | 0.772 |
Dominant model | ||||||||
GG(ref)/n(%) | 105 (67) | 25 (43) | 1 | ‒ | 96 (60) | 45 (52) | 1 | ‒ |
GA+AA/n(%) | 53 (33) | 33 (57) | 0.403 (0.186‒0.871) | 0.021 | 64 (40) | 42 (48) | 0.708 (0.354‒1.417) | 0.330 |
Recessive model | ||||||||
GG+GA(ref)/n(%) | 149 (94) | 52 (90) | 1 | ‒ | 146 (91) | 79 (91) | 1 | ‒ |
AA/n(%) | 9 (6) | 6 (10) | 0.360 (0.086‒1.502) | 0.161 | 14 (9) | 8 (9) | 0.981 (0.307‒3.316) | 0.974 |
Item | GG (n=271) | GA+AA (n=192) | P value |
---|---|---|---|
Gender (M/F)/n | 130/141 | 86/106 | 0.499 |
Age/year | 53.80±9.87 | 54.49±9.41 | 0.448 |
BMI/(kg·m-2) | 25.08±3.60 | 25.23±3.87 | 0.685 |
SBP/mmHg | 131.95±18.34 | 130.72±19.52 | 0.506 |
DBP/mmHg | 78.93±11.93 | 78.44±11.09 | 0.670 |
FBG/(mmol·L-1) | 7.65±2.56 | 7.37±2.54 | 0.276 |
2 h PG/(mmol·L-1) | 10.89±4.77 | 10.42±5.28 | 0.338 |
HbA1c/% | 8.36±2.85 | 7.90±2.65 | 0.094 |
GA/% | 21.69±13.40 | 19.34±8.51 | 0.048 |
HDL-Ch/(mmol·L-1) | 1.11±0.30 | 1.16±0.34 | 0.096 |
LDL-Ch/(mmol·L-1) | 3.20±0.80 | 3.18±0.79 | 0.795 |
TC/(mmol·L-1) | 5.09±1.25 | 5.05±1.25 | 0.719 |
TAG/(mmol·L-1) | 1.54 (1.09, 2.56) | 1.49 (0.95,2.43) | 0.570 |
FINS/(mU·L-1) | 8.25 (5.45, 12.94) | 7.03 (5.13, 12.20) | 0.387 |
2 h INS/(mU·L-1) | 36.39 (19.71,54.47) | 32.40 (20.10,47.80) | 0.854 |
HOMA-IR | 2.63 (1.47,4.78) | 2.22 (1.34,4.10) | 0.136 |
HOMA-β | 59.38 (31.46,89.13) | 55.57 (32.83,85.99) | 0.382 |
HOMA-IR① | 1.02±0.83 | 0.88±0.88 | 0.913 |
HOMA-β① | 3.95±0.84 | 3.95±0.78 | 0.983 |
Tab 4 Comparison of clinical features of different genotypes
Item | GG (n=271) | GA+AA (n=192) | P value |
---|---|---|---|
Gender (M/F)/n | 130/141 | 86/106 | 0.499 |
Age/year | 53.80±9.87 | 54.49±9.41 | 0.448 |
BMI/(kg·m-2) | 25.08±3.60 | 25.23±3.87 | 0.685 |
SBP/mmHg | 131.95±18.34 | 130.72±19.52 | 0.506 |
DBP/mmHg | 78.93±11.93 | 78.44±11.09 | 0.670 |
FBG/(mmol·L-1) | 7.65±2.56 | 7.37±2.54 | 0.276 |
2 h PG/(mmol·L-1) | 10.89±4.77 | 10.42±5.28 | 0.338 |
HbA1c/% | 8.36±2.85 | 7.90±2.65 | 0.094 |
GA/% | 21.69±13.40 | 19.34±8.51 | 0.048 |
HDL-Ch/(mmol·L-1) | 1.11±0.30 | 1.16±0.34 | 0.096 |
LDL-Ch/(mmol·L-1) | 3.20±0.80 | 3.18±0.79 | 0.795 |
TC/(mmol·L-1) | 5.09±1.25 | 5.05±1.25 | 0.719 |
TAG/(mmol·L-1) | 1.54 (1.09, 2.56) | 1.49 (0.95,2.43) | 0.570 |
FINS/(mU·L-1) | 8.25 (5.45, 12.94) | 7.03 (5.13, 12.20) | 0.387 |
2 h INS/(mU·L-1) | 36.39 (19.71,54.47) | 32.40 (20.10,47.80) | 0.854 |
HOMA-IR | 2.63 (1.47,4.78) | 2.22 (1.34,4.10) | 0.136 |
HOMA-β | 59.38 (31.46,89.13) | 55.57 (32.83,85.99) | 0.382 |
HOMA-IR① | 1.02±0.83 | 0.88±0.88 | 0.913 |
HOMA-β① | 3.95±0.84 | 3.95±0.78 | 0.983 |
Item | GG (n=130) | GA+AA (n=86) | P value |
---|---|---|---|
Age/year | 50.44±8.93 | 52.36±8.24 | 0.112 |
BMI/(kg·m-2) | 25.13±3.08 | 25.30±3.66 | 0.724 |
SBP/mmHg | 131.93±17.05 | 130.91±19.62 | 0.698 |
DBP/mmHg | 81.55±11.57 | 81.26±11.96 | 0.863 |
FBG/(mmol·L-1) | 8.25±2.55 | 7.34±2.46 | 0.016 |
2 h PG/(mmol·L-1) | 11.53±5.03 | 10.43±6.00 | 0.159 |
HbA1c/% | 8.81±3.10 | 7.89±2.79 | 0.037 |
GA/% | 22.23±9.02 | 19.98±9.84 | 0.116 |
HDL-Ch/(mmol·L-1) | 1.01±0.28 | 1.07±0.36 | 0.230 |
LDL-Ch/(mmol·L-1) | 3.20±0.81 | 3.14±0.78 | 0.637 |
TC/(mmol·L-1) | 5.08±1.42 | 4.89±1.16 | 0.311 |
TAG/(mmol·L-1) | 1.58 (1.17, 2.59) | 1.71 (1.18, 3.39) | 0.334 |
FINS/(mU·L-1) | 8.10 (5.60, 12.51) | 8.48 (5.24, 12.35) | 0.699 |
2 h INS/(mU·L-1) | 29.68 (17.53, 45.94) | 32.52 (19.72, 47.08) | 0.991 |
HOMA-IR | 2.81 (1.56, 4.94) | 2.39 (1.48, 3.99) | 0.267 |
HOMA-β | 47.62 (24.96, 73.33) | 52.38 (31.24, 85.09) | 0.151 |
HOMA-IR① | 1.05±0.78 | 0.89±0.75 | 0.176 |
HOMA-β① | 3.71±0.86 | 3.91±0.81 | 0.112 |
Tab 5 Comparison of clinical features of different genotypes in the males
Item | GG (n=130) | GA+AA (n=86) | P value |
---|---|---|---|
Age/year | 50.44±8.93 | 52.36±8.24 | 0.112 |
BMI/(kg·m-2) | 25.13±3.08 | 25.30±3.66 | 0.724 |
SBP/mmHg | 131.93±17.05 | 130.91±19.62 | 0.698 |
DBP/mmHg | 81.55±11.57 | 81.26±11.96 | 0.863 |
FBG/(mmol·L-1) | 8.25±2.55 | 7.34±2.46 | 0.016 |
2 h PG/(mmol·L-1) | 11.53±5.03 | 10.43±6.00 | 0.159 |
HbA1c/% | 8.81±3.10 | 7.89±2.79 | 0.037 |
GA/% | 22.23±9.02 | 19.98±9.84 | 0.116 |
HDL-Ch/(mmol·L-1) | 1.01±0.28 | 1.07±0.36 | 0.230 |
LDL-Ch/(mmol·L-1) | 3.20±0.81 | 3.14±0.78 | 0.637 |
TC/(mmol·L-1) | 5.08±1.42 | 4.89±1.16 | 0.311 |
TAG/(mmol·L-1) | 1.58 (1.17, 2.59) | 1.71 (1.18, 3.39) | 0.334 |
FINS/(mU·L-1) | 8.10 (5.60, 12.51) | 8.48 (5.24, 12.35) | 0.699 |
2 h INS/(mU·L-1) | 29.68 (17.53, 45.94) | 32.52 (19.72, 47.08) | 0.991 |
HOMA-IR | 2.81 (1.56, 4.94) | 2.39 (1.48, 3.99) | 0.267 |
HOMA-β | 47.62 (24.96, 73.33) | 52.38 (31.24, 85.09) | 0.151 |
HOMA-IR① | 1.05±0.78 | 0.89±0.75 | 0.176 |
HOMA-β① | 3.71±0.86 | 3.91±0.81 | 0.112 |
1 | Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045[J]. Diabetes Res Clin Pract, 2018, 138: 271-281. |
2 | Blad CC, Tang C, Offermanns S. G protein-coupled receptors for energy metabolites as new therapeutic targets[J]. Nat Rev Drug Discov, 2012, 11(8): 603-619. |
3 | Koliaki C, Doupis J. Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus[J]. Diabetes Ther, 2011, 2(2): 101-121. |
4 | Leech CA, Holz GG, Chepurny O, et al. Expression of cAMP-regulated guanine nucleotide exchange factors in pancreatic β-cells[J]. Biochem Biophys Res Commun, 2000, 278(1): 44-47. |
5 | Beinborn M, Worrall CI, McBride EW, et al. A human glucagon-like peptide-1 receptor polymorphism results in reduced agonist responsiveness[J]. Regul Pept, 2005, 130(1/2): 1-6. |
6 | Shalaby SM, Zidan HE, Shokry A, et al. Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients[J]. J Gene Med, 2017, 19(9/10): e2973. |
7 | Sathananthan A, Man CD, Micheletto F, et al. Common genetic variation in GLP1R and insulin secretion in response to exogenous GLP-1 in nondiabetic subjects: a pilot study[J]. Diabetes Care, 2010, 33(9): 2074-2076. |
8 | Kwak SH, Chae J, Lee S, et al. Nonsynonymous variants in PAX4 and GLP1R are associated with type 2 diabetes in an East Asian population[J]. Diabetes, 2018, 67(9): 1892-1902. |
9 | Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation[J]. Diabet Med, 1998, 15(7): 539-553. |
10 | Parthier C, Reedtz-Runge S, Rudolph R, et al. Passing the baton in class B GPCRs: peptide hormone activation via helix induction?[J]. Trends Biochem Sci, 2009, 34(6): 303-310. |
11 | Scott RA, Freitag DF, Li L, et al. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease[J]. Sci Transl Med, 2016, 8(341): 341ra76. |
12 | Anderson B, Carlson P, Laurenti M, et al. Association between allelic variants in the glucagon-like peptide 1 and cholecystokinin receptor genes with gastric emptying and glucose tolerance[J]. Neurogastroenterol Motil, 2020, 32(1): e13724. |
13 | Nishiya Y, Daimon M, Mizushiri S, et al. Nutrient consumption-dependent association of a glucagon-like peptide-1 receptor gene polymorphism with insulin secretion[J]. Sci Rep, 2020, 10(1): 16382. |
14 | Karras SN, Rapti E, Koufakis T, et al. Pharmacogenetics of glucagon-like peptide-1 agonists for the treatment of type 2 diabetes mellitus[J]. Curr Clin Pharmacol, 2017, 12(4): 202-209. |
15 | Jensterle M, Pirš B, Goričar K, et al. Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study[J]. Eur J Clin Pharmacol, 2015, 71(7): 817-824. |
16 | Ma X, Lu R, Gu N, et al. Polymorphisms in the glucagon-like peptide 1 receptor (GLP-1R) gene are associated with the risk of coronary artery disease in Chinese Han patients with type 2 diabetes mellitus: a case-control study[J]. J Diabetes Res, 2018, 2018: 1054192. |
17 | 房彬彬, 罗俊一, 李艳红, 等. GLP1R基因rs1042044多态性与2型糖尿病的相关性研究[J]. 新疆医科大学学报, 2021, 44(1): 8-11. |
18 | Li W, Li P, Li R, et al. GLP1R single-nucleotide polymorphisms rs3765467 and rs10305492 affect β cell insulin secretory capacity and apoptosis through GLP-1[J]. DNA Cell Biol, 2020, 39(9): 1700-1710. |
19 | 李蕊, 尹影, 徐曰东, 等. 胰升糖素样肽1受体基因多态性与2型糖尿病代谢指标的相关性研究[J]. 中华内分泌代谢杂志, 2019, 35(11): 945-949. |
20 | Han E, Park HS, Kwon O, et al. A genetic variant in GLP1R is associated with response to DPP-4 inhibitors in patients with type 2 diabetes[J]. Medicine (Baltimore), 2016, 95(44): e5155. |
21 | Dong M, Gao F, Pinon DI, et al. Insights into the structural basis of endogenous agonist activation of family B G protein-coupled receptors[J]. Mol Endocrinol, 2008, 22(6): 1489-1499. |
[1] | Hong YANG, Xin-xin HUANG, Chao LIU, Qing-song LIANG, Hua YANG, Jian-biao ZHANG, Jian XU, Ying-yi WANG, Hai-su WU, Qin-yu LÜ, Zheng-hui YI. Association study of synaptotagmin 2 gene polymorphisms with schizophrenia in Chinese Han population [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 16-22. |
[2] | Ning XU, Tian ZHOU, Guo-jun HOU, Nan SHEN, Yuan-jia TANG. Application of CRISPR/Cas9-mediated homologous recombination to the functional study of disease-associated genetic variants located in non-coding region [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(1): 8-15. |
[3] | WANG Ting-ting1, 2, LI Ming-jie1, LIN Ning1, NIU Yi-xin1, JIAN Wei-xia1, SU Qing1. Relationship between high serum uric acid level and short-term progression of albuminuria in hospitalized diabetic patients [J]. , 2019, 39(7): 754-. |
[4] | GAO Wei1, WANG Xue-jiao2, ZHEN Qin2, DING Xiao-ying2, XU Huan-bai2, WANG Yu-fan2, PENG Yong-de2. Analysis of risk factors of decreased heart rate variability in patients with type 2 diabetes mellitus [J]. , 2019, 39(6): 629-. |
[5] | WANG Ling-xiao, LIU Ting-ting, YANG Xiao-hui, YAO Zhi-qing, CAI Hui-zhen. Effect of Lycium barbarum polysaccharides on inflammatory cytokines in type 2 diabetes mellitus model mice without myeloid differentiation factor 88 gene [J]. , 2019, 39(2): 136-. |
[6] | CHEN Yan1, FANG Xin-yu1, WANG Ye-wei1, NI Jian-liang2, ZHANG Jiang-tao2, LU Wei-hong1, LI Tao3, ZHANG Deng-feng4, ZHANG Chen1. Association analysis of FOS gene rs1063169 polymorphism and Alzheimers disease in Han Chinese people [J]. , 2019, 39(1): 47-. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||